
New Drug Offers Hope for Ovarian Cancer Patients in England
NHS England has approved mirvetuximab soravtansine (Elahere) for women with platinum-resistant ovarian cancer, marking the first new drug for this condition in over 20 years. The treatment, administered every three weeks, delayed cancer progression and prolonged survival by an average of four months in clinical trials.







